BioNTech posts tripled Q1 vaccine sales but still flags full-year decline
BioNTech reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.;
Frankfurt: BioNTech said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer, but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales.
First-quarter revenues more than tripled from the year-earlier period, to 6.37 billion euros, as did quarterly net income, to 3.70 billion euros, the company said in a statement on Monday.
"As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance," finance chief Jens Holstein said.
BioNTech reiterated its 2022 vaccine revenue guidance of between 13 billion and 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.
Read also: BioNTech to expand clinical trial programme for more anti-Omicron vaccine options
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.